Efficacy PotentialThe Ph3 regimen of 100mg loading dose plus 50mg every two weeks could potentially increase drug exposure, possibly boosting its efficacy.

Safety ProfileLoni's safety profile looks promising versus competitors, with no dose-dependent adverse effects seen due to its lower drug concentrations.

Bears Say

Dosing ConcernsConcerns exist on a more frequent dosing interval for lonigutamab versus subcutaneous competition.

Financial ImpactThe price target adjusts from $6 to $5 due to the reduced pipeline spend after removal of uveitis from the model.

Pipeline SetbackAcelyrin's recent announcement that the PhII/III study evaluating izokibep in uveitis did not meet the trial's primary endpoint has led to a reduced sales projection.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

11.00% Insiders

2.74% Mutual Funds

49.84% Other Institutional Investors

93.34% Public Companies and Individual Investors

Detailed Ownership Overview >

SLRN FAQ

What was ACELYRIN, INC.’s price range in the past 12 months?

ACELYRIN, INC. lowest stock price was $1.84 and its highest was $7.25 in the past 12 months.

What is ACELYRIN, INC.’s market cap?

ACELYRIN, INC.’s market cap is $229.16M.

When is ACELYRIN, INC.’s upcoming earnings report date?

ACELYRIN, INC.’s upcoming earnings report date is Jun 12, 2025 which is 6 days ago.

How were ACELYRIN, INC.’s earnings last quarter?

ACELYRIN, INC. released its earnings results on Mar 27, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.863 by -$0.167.

Is ACELYRIN, INC. overvalued?

According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ACELYRIN, INC. pay dividends?

ACELYRIN, INC. pays a Notavailable dividend of $0.481 which represents an annual dividend yield of N/A. See more information on ACELYRIN, INC. dividends here

What is ACELYRIN, INC.’s EPS estimate?

ACELYRIN, INC.’s EPS estimate is -0.73.

How many shares outstanding does ACELYRIN, INC. have?

ACELYRIN, INC. has 100,954,000 shares outstanding.

What happened to ACELYRIN, INC.’s price movement after its last earnings report?

ACELYRIN, INC. reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.863. Following the earnings report the stock price went up 3.937%.

Which hedge fund is a major shareholder of ACELYRIN, INC.?

Currently, no hedge funds are holding shares in SLRN

ACELYRIN, INC. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-51.08%

Trailing 12-Months

Asset Growth

-37.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ACELYRIN, INC.

ACELYRIN, INC. (SLRN) is a biopharmaceutical company focused on identifying, developing, and commercializing transformative medicines. The company operates in the healthcare sector, specifically targeting unmet medical needs through innovative therapeutic solutions. ACELYRIN is dedicated to advancing a pipeline of drug candidates that address significant health conditions, leveraging cutting-edge research and development to bring new treatments to market.